Eden Biologics today announced completion of enrollment for Phase 1 PK Clinical Trial of Eden's lead product candidate EB1001, a Denosumab biosimilar. HSINCHU, TAIWAN, February 25, 2021 /EINPresswire.com/ — Eden Biologics, Inc., a global …
Feb
25
